Key result
Amlodipine linked to ~42% lower readmission odds versus no treatment or labetalol in hypertensive pregnancy.
Why the study?
Postnatal blood pressure management after hypertensive disorders of pregnancy is variable and supported by limited evidence despite its impact on maternal morbidity and hospital readmissions.
Does amlodipine reduce hospital readmission and improve blood pressure trajectories compared to no treatment or labetalol in women with hypertensive disorders of pregnancy in the early postpartum period?
Cohort (n=570)
Yes
Does amlodipine reduce hospital readmission and improve blood pressure trajectories compared to no treatment or labetalol in women with hypertensive disorders of pregnancy in the early postpartum period?
Odds Ratio: 0.58 (95% CI 0.35–0.94)
In women with hypertensive disorders of pregnancy, amlodipine at discharge is associated with a faster early blood pressure decline and lower odds of hospital readmission compared to labetalol or no treatment.
Amlodipine was associated with fewer readmissions in postpartum hypertension; hypothesis-generating versus labetalol, requiring randomized confirmation before practice change.
BACKGROUND: Hypertensive disorders of pregnancy (HDP) affect 8-10% of pregnancies. They are an important cause of maternal morbidity, with crucial implications for long-term cardiovascular health. Whilst antenatal blood pressure (BP) management is well described and evidence-based, postnatal treatment thresholds are higher, management varies, and supporting evidence is limited. OBJECTIVES: To characterise postnatal BP trajectories in women with HDP and assess the prevalence of severe hypertension and emergency hospital presentation. STUDY DESIGN AND MAIN OUTCOME MEASURES: A retrospective cohort study used routinely collected NHS data from three maternity sites from women exposed to antihypertensive medication either during pregnancy, or within six weeks postpartum. 15,884 BP readings from 570 women were analysed between May and November 2024. Mixed regression models assessed blood pressure trajectories across the treatment groups. RESULTS: Severe postnatal hypertension (≥160/110 mmHg) occurred in 39% of women. 29% required ≥1 readmission to maternity triage. Antihypertensives prescribing at discharge was highly variable, with 28 regimens used; 38% of women were discharged without antihypertensive medication. BP peaked five days postpartum, whereas the median discharge occurred on day three. Amlodipine was associated with lower odds of re-admission compared with no treatment (OR 0.58 [95% CI 0.35-0.94]) and labetalol (0.54 [0.50-0.58]), and with a faster early BP decline (p < 0.001). CONCLUSION: Postnatal hypertension following HDP is common and remains a major driver of re-attendance. Differences in BP profiles by discharge medication suggest that antihypertensive choice influences early postnatal outcomes. Prospective studies and trials are needed to inform prescribing practices and to reduce morbidity.
No takes yet. Share an insight, caveat, or question.
Moran et al. (2026) conducted a cohort in Hypertensive disorders of pregnancy (n=570). Amlodipine vs. No treatment and labetalol was evaluated on Re-admission to maternity triage (OR 0.58, 95% CI 0.35-0.94). In women with hypertensive disorders of pregnancy, amlodipine was associated with lower odds of re-admission compared with no treatment (OR 0.58; 95% CI 0.35-0.94) and labetalol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: